Moderna to join Nasdaq 100, replacing Warner Bros Discovery

Moderna (MRNA) will join the Nasdaq 100 on October 9, replacing Warner Bros Discovery (WBD). Moderna's stock has risen over sixfold this year, reaching a market cap of approximately $75 billion. Warner Bros Discovery will also be removed from several other major indexes due to its upcoming merger with Paramount Skydance.

Original reporting
Published Oct 5, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 6:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MRNA
Bullish
high confidence
Mentioned
$MRNA · $WBD
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$MRNABullishMed
01

Why it matters

The changes affect passive fund allocations and may trigger short‑term price moves in both stocks.

02

Market read

Index composition changes are a known driver of short‑term price action for the affected constituents.

03

What to watch

Potential dilution from the upcoming merger could offset index‑related buying for Warner Bros Discovery.

Relevance 7/10Novelty 7/10Timing: effective Oct 9 (Nasdaq-100 inclusion) and Oct 6 (Merger completion)

Background

Nasdaq announced a quarterly rebalancing, adding Moderna and removing Warner Bros Discovery as part of routine index maintenance.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna will be added to the Nasdaq-100 on Oct 9, reflecting its sixfold rally and $75bn market cap.

Expected impact

upward pressure as passive funds add shares

Evidence & confidence

Index additions trigger automatic buying by funds tracking the Nasdaq-100.

$WBDBearishHigh confidence
Context

Warner Bros Discovery will be removed from the Nasdaq-100 and other indexes after its merger with Paramount Skydance completes on Oct 6.

Expected impact

downward pressure as funds sell the stock

Evidence & confidence

Index removals cause passive fund outflows and can depress the share price.

Market effects

Biotech sector may see modest inflows as a high‑growth name joins a major index.

U.S. equity markets could see slight uplift in the Nasdaq-100 weighting.

Global index trackers will adjust holdings, affecting international fund flows.

Counterpoint

If the market has already priced Moderna's rally, the index addition may be a buy‑the‑rumor, not a catalyst.

Key entities

  • Moderna, Inc.

    Biotech firm joining the Nasdaq-100.

  • Warner Bros Discovery, Inc.

    Media company being removed from the Nasdaq-100 after its merger.

Related articles

$MRNAMedAI 8/10

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Moderna and Merck reported that their mRNA cancer vaccine, intismeran, reduced death or recurrence risk by 42% in a late-stage melanoma trial. The vaccine, combined with Merck's Keytruda, showed improved recurrence-free and metastasis-free survival rates compared to Keytruda alone. The companies plan to seek regulatory approval and presented the data at a medical conference.